Picard Medical, Inc. (PMI) Securities Class Action Update [February 10, 2026]

Investors Allege IPO Structure Enabled a Pump-and-Dump Scheme

• Case Name: Louie v. Picard Medical, Inc. et al
• Case No.: 5:26-cv-01024
• Jurisdiction: U.S. District Court, Northern District of California, San Jose Division
• Filed on: February 2, 2026
• Class Period: September 2, 2025-October 31, 2025

Introduction

Picard Medical, Inc. (“Picard” or the “Company”) is facing a federal securities class action after its newly public shares collapsed following a dramatic price surge that, according to the complaint, was fueled by coordinated promotional activity rather than fundamental news. The lawsuit alleges that Picard’s September 2025 IPO was structured in a way that made the stock uniquely vulnerable to social-media-driven manipulation, while key risks were never disclosed to investors. When the alleged promotional scheme unraveled in late October 2025, shareholders were left holding steep losses.

The case centers on a narrow class period, from September 2, 2025, the IPO date, through October 31, 2025, and raises questions not only about Picard’s disclosures, but about the growing risks embedded in ultra-low-float micro-cap offerings.

“Most PMI shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Picard Medical is a Delaware-incorporated medical device company headquartered in Tucson, Arizona. Its core operating subsidiary, SynCardia Systems, manufactures the SynCardia Total Artificial Heart, which the Company describes as the only FDA- and Health Canada-approved total artificial heart for commercial use in those markets.

Before going public, Picard spent years attempting to access the public markets. An earlier effort to list via a reverse merger with Altitude Acquisition Corp. failed, ending with Altitude’s liquidation in March 2024. Picard ultimately pursued a traditional IPO, which was approved in early September 2025, listing shares on Nasdaq under the ticker “PMI.”

Critically, the IPO made only about 4.25 million shares, roughly 5% of total equity, available to the public, leaving the vast majority of shares under insider or affiliate control. According to the complaint, the unusually small public float created conditions that made the stock vulnerable to volatility and manipulation in the weeks following the IPO

Promises Made vs. Reality

In its IPO prospectus and subsequent press releases, Picard positioned itself as a category leader. The Company emphasized its exclusive regulatory approvals, its installed base of more than 2,100 implants worldwide, and its long-term vision to develop a fully implantable next-generation artificial heart system.

Management highlighted revenue growth and improvements in certain operating metrics, including a narrowing of gross loss reported in the company’s financial results. In a September 15, 2025 press release, CEO Patrick N.J. Schnegelsberg stated that the Company had achieved “over 200% revenue growth year-over-year” and had strengthened its operating profile following the IPO.

What investors were not told, according to the lawsuit, was that the IPO’s unusually small public float and opaque share allocations created a heightened risk that PMI shares could be artificially inflated through coordinated online promotions, a pattern regulators had already observed in similar micro-cap offerings

Timeline of Alleged Misconduct and Disclosures

After pricing its IPO at $4.00 per share on September 2, 2025, PMI stock began climbing rapidly. Within weeks, shares surged to an intraday high of approximately $13.68 on October 23, 2025, despite what the complaint describes as an absence of fundamental news to justify the move.

During this run-up, investigators and market commentators allegedly identified PMI as the subject of coordinated social-media promotions involving impersonators posing as licensed financial professionals. These promotions, plaintiffs allege, circulated through platforms such as WhatsApp, Facebook, and other online forums.

The surge ended abruptly. On October 24, 2025, PMI shares collapsed by roughly 70%, falling back to around $4.00 in a single session. The Company responded by stating that it was “not aware of any undisclosed material change” that would explain the volatility. The complaint alleges that defendants’ public disclosures failed to adequately warn investors about risks associated with the stock’s trading dynamics

Investor Harm and Market Reaction

At its peak, Picard’s market capitalization approached $1 billion. After the collapse, that value evaporated almost overnight. Investors who purchased during the inflationary phase of the alleged scheme suffered substantial losses as the stock retraced to, and eventually below, its IPO price.

The complaint ties investor harm directly to the corrective disclosure event: once the artificial demand generated by online promotions dissipated, PMI’s share price rapidly adjusted downward. According to plaintiffs, this price correction revealed the extent to which earlier trading levels were disconnected from Picard’s actual fundamentals.

Litigation and Procedural Posture

The lawsuit, filed in the U.S. District Court for the Northern District of California, asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. Defendants include Picard Medical, several senior executives and directors, IPO underwriters, and the Company’s auditor.

Plaintiffs allege that defendants knowingly or recklessly failed to disclose material risks, disseminated misleading statements, and structured the IPO in a manner that facilitated manipulation. The complaint also pleads scienter, loss causation, and reliance under the fraud-on-the-market doctrine. The case is currently in its early stages, with lead-plaintiff proceedings expected to follow.

Shareholder Sentiment

Public retail discussion around Picard Medical shifted noticeably after the stock’s run-up and collapse. On Reddit, users in public trading forums described PMI as a suspected WhatsApp-driven pump-and-dump, with some posters saying they had received messages from purported “advisor” groups urging them to buy at specific price levels and share screenshots of their purchases. Other posters warned that the stock’s move looked detached from ordinary fundamentals and described sharp overnight losses after the drop.

Stocktwits also hosted an active PMI discussion board during this period, reflecting significant retail attention around the name. Taken together, those public discussions are directionally consistent with the complaint’s allegation that PMI’s unusually small float and online promotion activity contributed to a rapid rise and then a steep collapse in the stock price.

Analyst Commentary

At least one market commentator publicly questioned PMI’s trading activity before the October collapse. Edwin Dorsey of The Bear Cave publicly questioned PMI’s trading mechanics in late 2025. Dorsey publicly suggested PMI showed characteristics associated with stock manipulation, while the complaint separately alleges the company’s market value became disconnected from fundamentals during the run-up.

Furthermore, financial outlets such as Simply Wall St and Seeking Alpha published warnings regarding the low-float IPO trend that plagued the Nasdaq throughout late 2025. Related reporting contend that PMI’s unusually small public float made the stock vulnerable to volatility not tied to fundamental company developments. The complaint points to these public warnings and the broader low-float manipulation backdrop in arguing that the risks were foreseeable and should have been more fully disclosed to investors.

SEC Filings & Risk Factors

Central to the case are Picard’s SEC filings, including its Registration Statement, Prospectus, Forms 10-Q, 8-K, and proxy materials. Plaintiffs allege that these documents emphasized growth prospects and competitive positioning while omitting discussion of heightened manipulation risks associated with the Company’s capital structure and public float.

The complaint also challenges the adequacy of the Company’s risk factor disclosures, asserting that known patterns of fraud affecting similar low-float IPOs were not meaningfully addressed, even as such schemes proliferated across the market.

Conclusion: Implications for Investors

The PMI lawsuit highlights the risks that can arise when a newly public company with a very small public float experiences rapid, promotion-driven trading activity. For investors, the lawsuit serves as a reminder that extreme price movements, especially in newly public, thinly traded stocks, often carry risks that extend beyond traditional financial metrics.

As the litigation moves forward, the case will test whether the company and other defendants adequately disclosed the risks surrounding PMI’s stock structure and trading activity. For shareholders who purchased PMI during the alleged class period, the outcome could determine whether losses tied to that volatility are ultimately recoverable through the securities laws. But the case underscores a broader lesson: disclosure quality, float size, and trading dynamics can matter as much as product promise when assessing post-IPO risk.

How to Join the Picard Medical, Inc. (PMI) Class Action

• Confirm you purchased PMI shares during the relevant class period
• Review eligibility details related to the IPO and post-IPO trading window
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.